NMR (MRI and MRS) as an outcome measure

NMR (MRI and MRS) as an outcome measure
  • Contacts
  • Pierre Carlier
    Pierre Carlier
    Dr Pierre Carlier is a leading specialist in magnetic resonance imaging and spectroscopy of muscle...
  • Eugenio Mercuri
    Eugenio Mercuri
    Eugenio Mercuri Md PhD (Associate Professor in Pediatric Neurology): areas of expertise: congenital muscular dystrophy,...
  • Volker Straub
    Volker Straub
    Professor Volker Straub was founding joint co-ordinator of TREAT-NMD, and is an executive board member...
  • Kieren Hollingsworth
    Kieren Hollingsworth
    Dr Kieren Hollingsworth is a research associate in magnetic resonance imaging and spectroscopy based at...

With the development of quantitative approaches in imaging techniques for neuromuscular diseases, the possibility of using magnetic resonance imaging and spectroscopy as a non-invasive outcome measure to assess treatment response is becoming a reality. For this to be a realistic option in future trials, cross-centre comparability of results will be a prerequisite. In work led by Pierre Carlier's group at the Institut de Myologie, standard operating procedures (SOPs) for certain quantitative techniques have been developed by a multinational (and multi-platform) working group. A manuscript has been prepared for publication, and SOPs for the following techniques:

  • Acquisition of T1w images for qualitative evaluation of muscle involvement and topography of lesions in neuromuscular diseases
  • Quantification of muscle fat infiltration in neuromuscular diseases using Nuclear Magnetic Resonance imaging 3‐point Dixon or spectrally selective excitation techniques.
  • Quantitative evaluation of muscle edema or inflammation in neuromuscular diseases using nuclear magnetic resonance T2 measurement techniques

will appear in a special supplement edition of Neuromuscular Disorders in the near future.

The process of developing these SOPs and the collaborative work that has taken place as part of a multicentre MRI study of patients with LGMD2I (FKRP mutation) has enabled an overall consensus to be reached on the ideal protocol to apply in clinical studies to obtain quantitative results from MRI techniques, and it was therefore possible to use this work to form the foundations of the MRI section of a study protocol for a major multicentre dysferlinopathy project that is to start in the second half of 2012.

After the definition of the principal NMRI outcome measures was achieved, much optimization work had still to be performed, in order to obtain truly quantitative measurements. Post-processing procedures for B1 receiver inhomogeneities were designed and validated and are proposed as add-on for Dixon imaging. Fat contamination is a major source of bias for skeletal muscle T2 determination. A relatively simple and easily implementable algorithm has been developed, which realizes a deconvolution of the fat and water signal. B1 transmit misadjustments are sources of error in T2 determination. A method for selection of voxels with adequate magnetization nutation has been implemented and allows normal skeletal muscle T2 values to be ascribed within a 4ms range. All these optimizations are described in the SOPs and in the manuscript submitted for publication.

 
03 Sep 2012